107 related articles for article (PubMed ID: 11835209)
1. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats.
Stepensky D; Golomb G; Hoffman A
J Pharm Sci; 2002 Feb; 91(2):508-16. PubMed ID: 11835209
[TBL] [Abstract][Full Text] [Related]
2. Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin, synthetic eel calcitonin.
Azuma Y; Chokki M; Ohta T; Kiyoki M
Endocrinology; 1996 Jun; 137(6):2586-92. PubMed ID: 8641213
[TBL] [Abstract][Full Text] [Related]
3. Disposition of alendronate following local delivery in a rat jaw.
Yaffe A; Binderman I; Breuer E; Pinto T; Golomb G
J Periodontol; 1999 Aug; 70(8):893-5. PubMed ID: 10476897
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
[TBL] [Abstract][Full Text] [Related]
5. Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats.
Katsumi H; Nakatani M; Sano J; Abe M; Kusamori K; Kurihara M; Shiota R; Takashima M; Fujita T; Sakane T; Hibi T; Yamamoto A
Int J Pharm; 2010 Nov; 400(1-2):124-30. PubMed ID: 20816731
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
Altundal H; Sayrak H; Yurtsever E; Göker K
J Oral Maxillofac Surg; 2007 Mar; 65(3):508-16. PubMed ID: 17307600
[TBL] [Abstract][Full Text] [Related]
7. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
[TBL] [Abstract][Full Text] [Related]
8. Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma.
Alves AP; Pessoa Cdo O; Costa-Lotufo L; Moraes Filho MO
Acta Cir Bras; 2007; 22(6):457-64. PubMed ID: 18235934
[TBL] [Abstract][Full Text] [Related]
9. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort.
Mohan G; Perilli E; Parkinson IH; Humphries JM; Fazzalari NL; Kuliwaba JS
Osteoarthritis Cartilage; 2013 Oct; 21(10):1595-604. PubMed ID: 23827368
[TBL] [Abstract][Full Text] [Related]
10. Alendronate did not inhibit instability-induced bone resorption. A study in rats.
Astrand J; Aspenberg P
Acta Orthop Scand; 1999 Feb; 70(1):67-70. PubMed ID: 10191752
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evidence of normal bone with alendronate.
Hayes WC; Shea M; Rodan GA
Int J Clin Pract Suppl; 1999 Apr; 101():9-13. PubMed ID: 12669735
[TBL] [Abstract][Full Text] [Related]
12. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
13. Effect of alendronate administration on bone mineral density and bone strength in castrated rats.
Broulik PD; Rosenkrancová J; Růzicka P; Sedlácek R
Horm Metab Res; 2005 Jul; 37(7):414-8. PubMed ID: 16034712
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Cohen H; Alferiev IS; Mönkkönen J; Seibel MJ; Pinto T; Ezra A; Solomon V; Stepensky D; Sagi H; Ornoy A; Patlas N; Hägele G; Hoffman A; Breuer E; Golomb G
Pharm Res; 1999 Sep; 16(9):1399-406. PubMed ID: 10496656
[TBL] [Abstract][Full Text] [Related]
15. A rat model for testing pharmacologic treatments of pressure-related bone loss.
Astrand J; Skripitz R; Skoglund B; Aspenberg P
Clin Orthop Relat Res; 2003 Apr; (409):296-305. PubMed ID: 12671515
[TBL] [Abstract][Full Text] [Related]
16. Effect of Korean oriental medicine extract on bone mass as compared with alendronate in ovariectomized rats.
Lee JW; Jhee O; Yuan H; Kim T; Kim D; Lee M; Om A; Lee B; Park SK; Kang J
J Med Food; 2005; 8(3):369-76. PubMed ID: 16176149
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of alendronate.
Porras AG; Holland SD; Gertz BJ
Clin Pharmacokinet; 1999 May; 36(5):315-28. PubMed ID: 10384857
[TBL] [Abstract][Full Text] [Related]
18. A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model.
Toker H; Ozdemir H; Ozer H; Eren K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Nov; 114(5 Suppl):S146-52. PubMed ID: 23063391
[TBL] [Abstract][Full Text] [Related]
19. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
[TBL] [Abstract][Full Text] [Related]
20. [A study of the safety of rapid infusion of alendronate].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
Gan To Kagaku Ryoho; 1999 Feb; 26(3):345-51. PubMed ID: 10065098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
